Expression of CD55, CD59, and CD35 on red blood cells of β-thalassaemia patients

Kurtoǧllu, Ayşegül Uǧur; Koçtekin, Belkls; Kurtoğlu, Erdal; Yıldız, Mustafa; Bozkurt, Selen

doi:10.5114/ceji.2017.67321

Cited by 9 publications

(15 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In line with our findings, Obaid et al, Kurtoǧllu et al, and Zahran et al found that expression of CD55 levels of β-thalassaemia patients were significantly decreased compared to healthy controls. On the other hand, they found there was no significant difference in the percentage of CD59 marker expression between β-thalassaemia patients and healthy controls [11] [18] [19].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Role of Complement Regulatory Proteins (CD55, CD59, and CD35) on Red Blood Cells of β-Thalassaemia Patients

Mahmoud¹,

Nasef²,

Eldewi³

et al. 2021

OJBD

View full text Add to dashboard Cite

Background: β-thalassaemia (β-Thal) is an inherited chronic haemolytic anaemia resulting from absent or low level of synthesis of β-globin chains of haemoglobin A in erythropoietic cells. The complement system is an important part of innate immune response that may be implicated in red blood cell (RBC) lysis. Mammalian cells are provided with surface bound complement regulatory proteins (MCRPs) that regulate the activation of complement cascade, thus protecting them from uncontrolled complement-mediated lysis. Objective is to evaluate the role of complement regulatory proteins (CD55, CD59, and CD35) on red blood cells, and to explain the pathogenesis of anaemia in β-thalassemia major. Methods: This case-control study enrolled 74 β thalassemia major patients who were compared with 40 age and sex matched controls. We performed expression of CD55, CD59, and CD35 on RBCs using flow cytometry. Results: CD55 levels of β-thalassemia major patients (79.78% ± 18.54%) were significantly decreased compared to healthy controls (99.45% ± 0.59%) (P < 0.001). CD59 levels of β-thalassemia major patients (97.76% ± 1.72%) were significantly lower than in the controls (99.75% ± 0.36%) (P < 0.001), also CD35 levels were significantly lower in the β-thalassemia major patients (4.30% ± 4.66%) than in the control group (19.40% ± 10.90%) (P < 0.001). Conclusion: β-thalassemia major patients suffer from increased haemolysis and a consequent increase in their demand for blood transfusion. Complement-mediated haemolysis was shown in our study by decreased expression of CD55, CD59, and CD35 in β-thalassemia major patients. This allows complement deposition on RBCs and enhances or accelerates their lysis.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Decreases in complement regulatory protein (CrP) levels may predispose RBCs to destruction by complement activation. So, complement regulatory proteins are absolutely required to protect RBC from spontaneous complement damage that contributes to the development of anaemia [11].…”

Section: Introductionmentioning

confidence: 99%

Role of Complement Regulatory Proteins (CD55, CD59, and CD35) on Red Blood Cells of β-Thalassaemia Patients

Mahmoud¹,

Nasef²,

Eldewi³

et al. 2021

OJBD

View full text Add to dashboard Cite

show abstract

“…Low CD55 levels in patients with β-TM indicate a role of the complement regulatory proteins, in the pathogenesis of haemolysis in this disorder, and therefore, a crucial role in the development of chronic complications described in these patients [50].…”

Section: β-Thalassemiamentioning

confidence: 93%

Thrombotic risk in paroxysmal nocturnal hemoglobinuria-like (PNH-like) phenotype

Carlisi

Mancuso

Caimi

et al. 2021

View full text Add to dashboard Cite

The complement system is an essential component of the innate immune defence that, if overly activated, may damage organs and tissues. For this reason, there is a fine complement regulatory system. The complement modulation system includes two proteins with important regulatory activity, CD55 or decay accelerating factor (DAF) and CD59 or membrane inhibitor of reactive lysis (MIRL). The paroxysmal nocturnal hemoglobinuria (PNH) is a clonal and non-neoplastic disease characterized by intravascular haemolysis, occurrence of thrombosis and bone marrow failure. In clinical practice, in opposition to PNH, a variety of pathological conditions have been observed with an acquired and non-genetic deficiency of the regulatory proteins CD55 and CD59. This abnormal, non-clonal, reduced expression of complement regulatory proteins configures what we may define as PNH-like phenotype. Similarly to PNH, even in the PNH-like phenotype diseases there has been a greater exposure to the mediated complement cellular lysis and, a likely increased risk of thromboembolic events. Therefore, the knowledge of the potential roles of the complement system becomes necessary for a deeper understanding of several pathological conditions and for an improved clinical management of the patients.

show abstract

“…The pellets were suspended in sheath fluid. The optimal concentration for each antibody was determined by titration experiments 11Figure 1.Flow cytometric analyses of CD35, CD55 and CD59 on leukocytes:EDTA-treated blood was mixed with the following monoclonal antibodies; FITC-conjugated CD35, PE-conjugated CD55 and FITC-conjugated CD59; the samples were incubated for 20 mins in the dark at room temperature.…”

Section: Methodsmentioning

confidence: 99%

“…The pellets were suspended in sheath fluid. The optimal concentration for each antibody was determined by titration experiments 11…”

Section: Methodsmentioning

confidence: 99%

Expression levels of complement regulatory proteins (CD35, CD55 and CD59) on peripheral blood cells of patients with chronic kidney disease

Eldewi¹,

Alhabibi²,

Sayed³

et al. 2019

IJGM

View full text Add to dashboard Cite

BackgroundAltered regulation of the complement system is associated with multiple kidney diseases. CD35, CD55 and CD59 regulate the complement system, and changes in their expression have previously been linked with kidney disease. This study assessed whether changes in the expression levels of these proteins are associated specifically with chronic kidney disease (CKD) to understand its pathogenesis.Materials and methodsSixty CKD patients and 60 age-matched controls were enrolled and divided into two groups: Group I (n=30 pediatric patients and n=30 controls) and Group II (n=30 adult patients and n=30 controls). The expression of CD35, CD55 and CD59 on peripheral blood cells was evaluated by flow cytometry as the proportion of positive cells expressing the marker and mean fluorescence intensity (MFI), also the relation of these markers to the stage of CKD was also evaluated.ResultsPediatric and adult CKD patients had significantly lower proportion of erythrocytes expressing CD35, CD55 and CD59 than healthy controls (P<0.001). In pediatric CKD patients, there was no significant difference in the three studied markers on neutrophils, lymphocytes and monocytes. The changes in expression of CD35, CD55 and CD59 on leukocytes were more pronounced in adult patients, who had lower proportion of CD59-positive neutrophils, CD35- and CD59-positive lymphocytes, and CD59-positive monocytes, as well as lower expression of CD59 on neutrophils and monocytes than adult controls (P<0.001, P=0.019, P<0.001, P=0.026, P<0.001 and P=0.003, respectively). The eGFR directly correlated with the proportion of positivity of some of those markers on peripheral leukocytes while there was inverse correlation between the disease stage and the same markers.ConclusionThere are alterations in the patterns of expression of complement regulatory proteins CD35, CD55 and CD59 on peripheral blood cells of patients with CKD compared with healthy controls.

show abstract

Expression of CD55, CD59, and CD35 on red blood cells of β-thalassaemia patients

Cited by 9 publications

References 27 publications

Role of Complement Regulatory Proteins (CD55, CD59, and CD35) on Red Blood Cells of <i>β</i>-Thalassaemia Patients

Role of Complement Regulatory Proteins (CD55, CD59, and CD35) on Red Blood Cells of <i>β</i>-Thalassaemia Patients

Thrombotic risk in paroxysmal nocturnal hemoglobinuria-like (PNH-like) phenotype

<p>Expression levels of complement regulatory proteins (CD35, CD55 and CD59) on peripheral blood cells of patients with chronic kidney disease</p>

Contact Info

Product

Resources

About

Expression of CD55, CD59, and CD35 on red blood cells of β-thalassaemia patients

Cited by 9 publications

References 27 publications

Role of Complement Regulatory Proteins (CD55, CD59, and CD35) on Red Blood Cells of &lt;i&gt;β&lt;/i&gt;-Thalassaemia Patients

Role of Complement Regulatory Proteins (CD55, CD59, and CD35) on Red Blood Cells of &lt;i&gt;β&lt;/i&gt;-Thalassaemia Patients

Thrombotic risk in paroxysmal nocturnal hemoglobinuria-like (PNH-like) phenotype

<p>Expression levels of complement regulatory proteins (CD35, CD55 and CD59) on peripheral blood cells of patients with chronic kidney disease</p>

Contact Info

Product

Resources

About

Role of Complement Regulatory Proteins (CD55, CD59, and CD35) on Red Blood Cells of <i>β</i>-Thalassaemia Patients

Role of Complement Regulatory Proteins (CD55, CD59, and CD35) on Red Blood Cells of <i>β</i>-Thalassaemia Patients